跳至主要内容
临床试验/EUCTR2013-000100-41-BE
EUCTR2013-000100-41-BE进行中(未招募)不适用

Histological study of the (intravenously injected) Indocyanine Green (ICG)distribution in tumour bearing breasts and in axillary pieces of dissection - Histological distribution of ICG in tumor bearing breast and CALND

Jules Bordet Institute0 个研究点开始时间: 2013年2月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Patients with histo-pathological diagnosis of mammary cancer who are
  • candidate for mastectomy with complete axillary node dissection,
  • - Informed consent form signed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Diagnosis of mammary cancer established, either by tumorectomy, or
  • by gross biopsy,
  • - Operation foreseen after neo-adjuvant chemotherapy,
  • - Age less than18 years old.
  • - In pre-menopausal women, operation foreseen during the second
  • phase of their cycle,
  • - Inability to give informed consent.
  • - History of allergy or hypersensitivity against the investigational
  • product (its active substance or ingredients), to iodine or to shellfish.
  • - Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal,
  • multifocal or dissemi-nated autonomies of the thyroid gland.
  • - Documented coronary disease.
  • - Advanced renal impairment (creatinine > 1,5mg/dl).
  • - During the 2 weeks before the enrolment, concurrent medication which
  • reduces or increases the extinction of ICG (i.e. anticonvulsants,
  • haloperidol and Heparin).
  • - Pregnancy, breastfeeding

研究者

相似试验